The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | IPSS-M: prognostic power in HMA-treated MDS patients
Samuel Urrutia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, speaks on the application of the recently developed Molecular International Prognostic Scoring System (IPSS-M) for classifying myelodysplastic syndromes (MDS) and measuring response to hypomethylating agents (HMA) based on genomic features. In a retrospective study, no definitive correlation between genomic characteristics and response to HMAs was identified, but a trend suggested that higher-risk patients may exhibit a more favorable response. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
